Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,174,935
  • Shares Outstanding, K 152,520
  • Annual Sales, $ 113,310 K
  • Annual Income, $ -57,510 K
  • EBIT $ -84 M
  • EBITDA $ -74 M
  • 60-Month Beta -1.20
  • Price/Sales 19.13
  • Price/Cash Flow N/A
  • Price/Book 11.32

Options Overview Details

View History
  • Implied Volatility 67.64% ( -3.33%)
  • Historical Volatility 170.86%
  • IV Percentile 14%
  • IV Rank 21.22%
  • IV High 195.68% on 07/18/24
  • IV Low 33.14% on 05/20/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 701
  • Volume Avg (30-Day) 1,032
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 16,075
  • Open Int (30-Day) 17,728

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 6
  • High Estimate 0.10
  • Low Estimate -0.40
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.66 +12.64%
on 11/19/24
16.74 -14.79%
on 11/11/24
-1.05 (-6.86%)
since 10/18/24
3-Month
5.04 +182.94%
on 09/06/24
16.74 -14.79%
on 11/11/24
+8.37 (+142.11%)
since 08/20/24
52-Week
3.50 +307.43%
on 02/14/24
16.74 -14.79%
on 11/11/24
+9.06 (+174.23%)
since 11/20/23

Most Recent Stories

More News
Wave Life Sciences CEO to Participate in Analyst-led Fireside Chat at Jefferies London Healthcare Conference

Wave Life Sciences CEO Paul Bolno will speak at the Jefferies London Healthcare Conference on November 20, 2024.Quiver AI SummaryWave Life Sciences Ltd. announced that CEO Paul Bolno will participate in...

WVE : 14.26 (+0.35%)
Wave Life Sciences to Present at Jefferies London Healthcare Conference

WVE : 14.26 (+0.35%)
Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences: Q3 Earnings Snapshot

WVE : 14.26 (+0.35%)
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

WVE : 14.26 (+0.35%)
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

WVE : 14.26 (+0.35%)
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

WVE : 14.26 (+0.35%)
1 Brand-New Big Reason to Buy This Biotech Stock Right Now

This stock currently has a good balance of risk and potential rewards.

WVE : 14.26 (+0.35%)
Wave Life Sciences Rockets 70% on Historic RNA Editing Success

Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases.

WFC : 73.58 (+0.20%)
WVE : 14.26 (+0.35%)
RJF : 162.18 (-0.27%)
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

WVE : 14.26 (+0.35%)
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

WVE : 14.26 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 15.18
2nd Resistance Point 14.83
1st Resistance Point 14.55
Last Price 14.26
1st Support Level 13.92
2nd Support Level 13.57
3rd Support Level 13.29

See More

52-Week High 16.74
Last Price 14.26
Fibonacci 61.8% 11.68
Fibonacci 50% 10.12
Fibonacci 38.2% 8.56
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar